UNLABELLED: T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have focused on chemotherapy or small molecules. SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s40364-020-00234-z.

Department 1 of Internal Medicine Center for Integrated Oncology The University of Cologne Cologne Germany

Department of Cell Biology and Immunology Centro de Biología Molecular Severo Ochoa CSIC UAM Madrid Spain

Department of Hemato Oncology Faculty Hospital Olomouc Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Hematology Hematology Research Unit Helsinki Helsinki University Hospital Comprehensive Cancer Center Helsinki Finland

Hematology Department Hospital Universitario de La Princesa IIS IP Madrid Spain

IMMED S L Immunological and Medicinal Products Madrid Spain

Immune System Development and Function Unit Centro de Biología Molecular Severo Ochoa CSIC UAM Madrid Spain

Immunology Department Hospital Universitario de La Princesa IIS IP C Diego de León 62 28006 Madrid Spain

Methodology Unit Hospital Universitario de La Princesa IIS IP Madrid Spain

Translational Immunology Research Program and Department of Clinical Chemistry University of Helsinki Helsinki Finland

Universidad Autónoma de Madrid Madrid Spain

Zobrazit více v PubMed

Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538–551. doi: 10.1182/blood-2012-01-380139. PubMed DOI

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132–1143. doi: 10.1182/blood.2019000402. PubMed DOI PMC

Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328–335. doi: 10.1182/blood-2004-01-0002. PubMed DOI

Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269–3274. doi: 10.1182/blood.V78.12.3269.3269. PubMed DOI

Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;103(2):110–116. doi: 10.1016/S0165-4608(97)00410-X. PubMed DOI

Durig J, Bug S, Klein-Hitpass L, Boes T, Jons T, Martin-Subero JI, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv (14)(q11q32) Leukemia. 2007;21(10):2153–2163. doi: 10.1038/sj.leu.2404877. PubMed DOI

Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, et al. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica. 2009;94(4):518–527. doi: 10.3324/haematol.2008.001347. PubMed DOI PMC

Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721–1726. doi: 10.1182/blood.V98.6.1721. PubMed DOI

Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15(7):2667–2672. doi: 10.1200/JCO.1997.15.7.2667. PubMed DOI

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258–2267. doi: 10.1002/cncr.27972. PubMed DOI

Dearden C. B- and T-cell prolymphocytic leukemia: antibody approaches. Hematology Am Soc Hematol Educ Program. 2012;2012:645–651. doi: 10.1182/asheducation.V2012.1.645.3798657. PubMed DOI

Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118(22):5799–5802. doi: 10.1182/blood-2011-08-372854. PubMed DOI

Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205–213. doi: 10.1200/JCO.2002.20.1.205. PubMed DOI

Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27(32):5425–5430. doi: 10.1200/JCO.2009.22.6688. PubMed DOI PMC

Yong HX, Linn YC, Ong KH, Tan D. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia. Leuk Res. 2012;36(8):e163–e165. doi: 10.1016/j.leukres.2012.04.031. PubMed DOI

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010;149(6):907–910. doi: 10.1111/j.1365-2141.2010.08134.x. PubMed DOI

Herling M. Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? Eur J Haematol. 2015;94(3):191–192. doi: 10.1111/ejh.12462. PubMed DOI

Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, et al. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012;26(5):972–976. doi: 10.1038/leu.2011.304. PubMed DOI

Hasegawa H, Nomura T, Kohno M, Tateishi N, Suzuki Y, Maeda N, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood. 2000;95(1):30–38. doi: 10.1182/blood.V95.1.30. PubMed DOI

Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, et al. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 2005;152(2):258–264. doi: 10.1111/j.1365-2133.2004.06325.x. PubMed DOI

Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009;459(7249):1000–1004. doi: 10.1038/nature08020. PubMed DOI PMC

Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, et al. The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. Haematologica. 2017;102(2):346–355. doi: 10.3324/haematol.2016.147744. PubMed DOI PMC

Cuesta-Mateos C, Lopez-Giral S, Alfonso-Perez M, de Soria VG, Loscertales J, Guasch-Vidal S, et al. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Exp Hematol. 2010;38(9):756–764. doi: 10.1016/j.exphem.2010.05.003. PubMed DOI

Redondo-Munoz J, Jose Terol M, Garcia-Marco JA, Garcia-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood. 2008;111(1):383–386. doi: 10.1182/blood-2007-08-107300. PubMed DOI

Alfonso-Perez M, Lopez-Giral S, Quintana NE, Loscertales J, Martin-Jimenez P, Munoz C. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol. 2006;79(6):1157–1165. doi: 10.1189/jlb.1105623. PubMed DOI

Cuesta-Mateos C, Loscertales J, Kreutzman A, Colom-Fernandez B, Portero-Sainz I, Perez-Villar JJ, et al. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunol Immunother. 2015;64(6):665–676. doi: 10.1007/s00262-015-1670-z. PubMed DOI PMC

van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2−/− gammac−/− double-mutant mice. Blood. 2003;102(7):2522–2531. doi: 10.1182/blood-2002-10-3241. PubMed DOI

Garaulet G, Alfranca A, Torrente M, Escolano A, Lopez-Fontal R, Hortelano S, et al. IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Mol Ther. 2013;21(1):119–130. doi: 10.1038/mt.2012.131. PubMed DOI PMC

Lopez-Giral S, Quintana NE, Cabrerizo M, Alfonso-Perez M, Sala-Valdes M, De Soria VG, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 2004;76(2):462–471. doi: 10.1189/jlb.1203652. PubMed DOI

Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002;169(1):424–433. doi: 10.4049/jimmunol.169.1.424. PubMed DOI

Legler DF, Uetz-von Allmen E, Hauser MA. CCR7: roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol. 2014;54:78–82. doi: 10.1016/j.biocel.2014.07.002. PubMed DOI

Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol. 2002;24(1):1–13. doi: 10.1046/j.1365-2257.2002.00135.x. PubMed DOI

del Pozo MA, Nieto M, Serrador JM, Sancho D, Vicente-Manzanares M, Martinez C, et al. The two poles of the lymphocyte: specialized cell compartments for migration and recruitment. Cell Adhes Commun. 1998;6(2–3):125–133. doi: 10.3109/15419069809004468. PubMed DOI

Stein JV, Soriano SF, M'Rini C, Nombela-Arrieta C, de Buitrago GG, Rodriguez-Frade JM, et al. CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway. Blood. 2003;101(1):38–44. doi: 10.1182/blood-2002-03-0841. PubMed DOI

Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene. 2007;26(50):7081–7091. doi: 10.1038/sj.onc.1210519. PubMed DOI

Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185–191. doi: 10.1016/S0145-2126(97)00158-6. PubMed DOI

Smith SD, McFall P, Morgan R, Link M, Hecht F, Cleary M, et al. Long-term growth of malignant thymocytes in vitro. Blood. 1989;73(8):2182–2187. doi: 10.1182/blood.V73.8.2182.2182. PubMed DOI

Patil P, Cieslak A, Bernhart SH, Toprak UH, Wagener R, Lopez C, et al. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. Genes Chromosom Cancer. 2020;59(4):261–7. 10.1002/gcc.22821. PubMed

Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97(7):3028–3033. doi: 10.1073/pnas.97.7.3028. PubMed DOI PMC

Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(26):12530–12534. doi: 10.1073/pnas.91.26.12530. PubMed DOI PMC

Chiaretti S, Gianfelici V, O'Brien SM, Mullighan CG. Advances in the genetics and therapy of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2016;35:e314–e322. doi: 10.1200/EDBK_156628. PubMed DOI

Bertilaccio MT, Scielzo C, Simonetti G, Ten Hacken E, Apollonio B, Ghia P, et al. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia. 2013;27(3):534–540. doi: 10.1038/leu.2012.268. PubMed DOI

Rehm A, Mensen A, Schradi K, Gerlach K, Wittstock S, Winter S, et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood. 2011;118(4):1020–1033. doi: 10.1182/blood-2010-11-321265. PubMed DOI

Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99(8):2977–2984. doi: 10.1182/blood.V99.8.2977. PubMed DOI

Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999;162(5):2472–2475. PubMed

Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011;30:51. doi: 10.1186/1756-9966-30-51. PubMed DOI PMC

Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol. 2007;8(11):1255–1265. doi: 10.1038/ni1513. PubMed DOI

Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao S, et al. Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen. J Hematol Oncol. 2014;7:71. doi: 10.1186/s13045-014-0071-7. PubMed DOI PMC

Despouy G, Joiner M, Le Toriellec E, Weil R, Stern MH. The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. Blood. 2007;110(13):4406–4416. doi: 10.1182/blood-2006-11-059501. PubMed DOI

Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328–337. doi: 10.1182/blood-2007-07-101519. PubMed DOI PMC

Dyer MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol. 1997;97(3):669–672. doi: 10.1046/j.1365-2141.1997.1062924.x. PubMed DOI

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–56. doi: 10.1038/35065016. PubMed DOI

Graham RL, Cooper B, Krause JR. T-cell prolymphocytic leukemia. Proc (Baylor Univ Med Cent) 2013;26(1):19–21. doi: 10.1080/08998280.2013.11928902. PubMed DOI PMC

Birhiray RE, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, et al. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia. 2002;16(5):861–864. doi: 10.1038/sj.leu.2402471. PubMed DOI

Tuset E, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42(6):1379–1383. doi: 10.1080/10428190127515. PubMed DOI

Andersson EI, Putzer S, Yadav B, Dufva O, Khan S, He L, et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2017;2017(14):252. PubMed

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gultekin S, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499–2503. doi: 10.1182/blood-2017-05-785683. PubMed DOI

He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, et al. Patient-customized drug combination prediction and testing for T-cell Prolymphocytic leukemia patients. Cancer Res. 2018;2018(26):0008–5472. PubMed

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Putzer S, von Jan J, et al. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697. doi: 10.1038/s41467-017-02688-6. PubMed DOI PMC

Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045–1052. doi: 10.1046/j.1523-1747.2003.12555.x. PubMed DOI

Kagdi HH, Demontis MA, Fields PA, Ramos JC, Bangham CR, Taylor GP. Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping. Cancer Med. 2017;6(1):298–309. doi: 10.1002/cam4.928. PubMed DOI PMC